Identification of short peptide sequences in the nanofiltration permeate of a bioactive whey protein hydrolysate by Le Maux, Solène et al.
DOI: 10.1016/j.foodres.2015.09.012 
1 
Identification of short peptide sequences in the nanofiltration permeate 1 
of a bioactive whey protein hydrolysate 2 
 3 
Solène Le Maux
a,‡
, Alice B. Nongonierma
a,‡
, Brian Murray
b
, Phil M. Kelly
b
 & Richard J. 4 
FitzGerald
a,
* 5 
 6 
 7 
 8 
a
 Department of Life Sciences and Food for Health Ireland (FHI), University of Limerick, 9 
Limerick, Ireland. 10 
b 
Teagasc Food Research Centre, Moorepark and Food for Health Ireland (FHI), Fermoy, 11 
Co. Cork, Ireland 12 
 13 
‡
 These two authors contributed equally 14 
 15 
Please cite as:  
Le Maux, S., Nongonierma, A. B., Murray, B., Kelly, P. M., & FitzGerald, R. J. (2015). 
Identification of short peptide sequences in the nanofiltration permeate of a bioactive 
whey protein hydrolysate. Food Research International, 77, 534-539. 
 16 
* Corresponding author: Dick.FitzGerald@ul.ie 17 
Tel: +353 (0) 61 202598 18 
Fax: + 353 (0) 61 331490 19 
20 
 2 
Abstract 21 
 22 
Short peptides in food protein hydrolysates are of significant interest as they may be 23 
highly bioactive whilst also being bioavailable. A dipeptidyl peptidase IV (DPP-IV) 24 
inhibitory whey protein hydrolysate (WPH) was fractionated using nanofiltration (NF) with a 25 
200 Da MWCO membrane. The DPP-IV half maximal inhibitory concentration of the NF 26 
permeate (IC50 = 0.66 ± 0.08 mg protein equivalent mL
-1
) was significantly more potent (P > 27 
0.05) than that of the starting WPH (IC50 = 0.94 ± 0.24 mg protein equivalent mL
-1
) and 28 
associated retentate (IC50 = 0.82 ± 0.13 mg protein equivalent mL
-1
). This confirmed the 29 
contribution of short peptides within the NF permeate to the overall DPP-IV inhibitory 30 
activity. An hydrophilic interaction liquid chromatography (HILIC-) and reverse-phase (RP-) 31 
liquid chromatography tandem mass spectrometry (LC-MS/MS) strategy, based on two 32 
retention time models, allowed detection of eight free amino acids and eight di- to 33 
tetrapeptides in the NF permeate. The potential sequences of the peptides within the NF 34 
permeate were then ranked on the basis of their highest probability of occurrence. 35 
Confirmatory study with synthetic peptides showed that valine-alanine (VA), valine-leucine 36 
(VL), tryptophan-leucine (WL) and tryptophan-isoleucine (WI), displayed DPP-IV IC50 37 
values < 170 µM. The NF and LC-MS strategies employed herein represent a new approach 38 
for the targeted identification of short peptides within bioactive food protein hydrolysates. 39 
 40 
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1. Introduction 45 
There is a growing interest in the utilisation of naturally-derived food products with 46 
health benefits such as antioxidant, antidiabetic and antihypertensive properties (Korhonen & 47 
Pilhanto, 2006; Li-Chan, 2015). Short peptide sequences are of particular interest as they 48 
have been associated, in certain instances, with both high bioactive potency and 49 
bioavailability (Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 50 
2011). This may be due to the fact that specific short peptides may be stable to 51 
gastrointestinal digestion and be absorbed intact in the intestinal epithelium (Foltz et al., 52 
2007). 53 
Enzymatic hydrolysis of milk proteins is a strategy frequently used for the generation 54 
of bioactive peptides. However, milk protein hydrolysates can contain a complex mixture of 55 
peptides. Therefore, fractionation of milk protein hydrolysates is employed to: (i) generate 56 
fractions enriched in bioactive peptides and (ii) reduce their compositional complexity, which 57 
may help in subsequent peptide identification. 58 
To date, the most frequently used techniques to separate peptides have been based on 59 
membrane processing and/or chromatographic separation (Bazinet & Firdaous, 2013; 60 
Poliwoda & Wieczorek, 2009). Nanofiltration (NF) has been utilised to enrich milk protein 61 
hydrolysates in bioactive peptides. It has been shown that both the molecular mass and 62 
peptide charge affect peptide transmission through NF membranes (Pouliot, 2008; Pouliot, 63 
Gauthier, & L'Heureux, 2000). 64 
Food protein-derived bioactive peptides can differ in length (generally < 6 amino 65 
acids) and physicochemical properties (Panchaud, Affolter, & Kussmann, 2012). For 66 
example, in the case of dietary antidiabetic peptides, several di- and tripeptides have been 67 
shown to be relatively potent in vitro (Lacroix & Li-Chan, 2012; Nongonierma & FitzGerald, 68 
2014). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a strategy 69 
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commonly used to identify specific peptide sequences within food protein hydrolysates. 70 
However, LC-MS/MS detection of short peptides within food protein hydrolysates still 71 
presents several technical challenges. This is linked to the fact that a number of different 72 
peptide sequences can correspond to the same molecular mass. Therefore, the application of 73 
different separation strategies prior to MS detection can provide additional information to 74 
allow for short peptide identification. This is the case for chromatographic separation as 75 
peptide retention on a chromatographic matrix depends both on the sequence and the 76 
chromatographic conditions (Zou, Zhang, Hong, & Lu, 1992). The retention time of short 77 
peptides can be predicted using algorithm models based on properties such as peptide size 78 
and amino acid position within the peptide sequence (i.e., at the N-, the C-terminus or within 79 
the peptide sequence) (Krokhin, 2006; Le Maux, Nongonierma, & FitzGerald, 2015; Meek, 80 
1980; Tripet et al., 2007). Furthermore, the combinations of different separation modes such 81 
as hydrophilic interaction liquid chromatography (HILIC) and reverse-phase (RP) 82 
chromatography have been shown to further enhance the accuracy of short peptide 83 
identification (Harscoat-Schiavo et al., 2012). 84 
The aim of this study was to validate a strategy involving NF, LC-MS/MS and 85 
retention time prediction for the selective enrichment and specific identification of short 86 
peptides in a bioactive protein hydrolysate. To support this approach, an antidiabetic in vitro 87 
bioassay measuring dipeptidyl peptidase IV (DPP-IV) inhibition was employed. DPP-IV is a 88 
metabolic enzyme which has been identified in the degradation of incretins (glucose 89 
dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)), resulting 90 
in a loss in their insulinotropic properties in vivo (Juillerat-Jeanneret, 2014). Di- and 91 
tripeptides have mainly been identified using in silico digestion followed by confirmatory 92 
studies with synthetic peptides  as well as peptide library approaches (Hikida, Ito, Motoyama, 93 
Kato, & Kawarasaki, 2013; Lan et al., 2015; Nongonierma & FitzGerald, 2013a; Tulipano, 94 
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Sibilia, Caroli, & Cocchi, 2011). However, to our knowledge, di- and tripeptides with DPP-95 
IV inhibitory properties have to date not been identified within milk protein hydrolysates by 96 
LC-MS. 97 
This study was assessed using a whey protein hydrolysate (WPH) with DPP-IV 98 
inhibitory activity. NF of the WPH was used to enrich for short peptides in the permeate. 99 
Furthermore, milk derived  short peptides could be detected and their overall contribution to 100 
DPP-IV inhibitory properties was assessed using a confirmatory study. 101 
 102 
 103 
2. Materials and methods 104 
 105 
2.1. Reagents 106 
Trifluoroacetic acid (TFA), tris(hydroxymethyl)aminomethane (TRIS), Gly-Pro-pNA, 107 
diprotin A (IPI), porcine DPP-IV (≥ 10 units mg-1 protein), high pressure liquid 108 
chromatography (HPLC) and MS grade water and acetonitrile (MeCN) were obtained from 109 
Sigma Aldrich (Dublin, Ireland). Hydrochloric acid (HCl) and sodium hydroxide (NaOH) 110 
were from VWR (Dublin, Ireland). The synthetic peptides cysteine-isoleucine-valine-leucine 111 
(CIVL) and leucine-cysteine-valine-leucine (LCVL) were from Genscript (Piscataway, NJ, 112 
USA) while glycine-isoleucine (GI), leucine-glycine (LG), serine-valine (SV), tyrosine-113 
isoleucine (YI), tyrosine-leucine (YL), isoleucine-tyrosine (IY) and isoleucine-glycine (IG) 114 
were from Bachem (Bubendorf, Germany). Standard peptides (purity ≥ 95% (w/w)) used for 115 
the retention time prediction models were purchased from Bachem, GenScript or Thermo 116 
Fisher Scientific (Waltham, MA, USA) as per Le Maux et al. (2015). The whey protein 117 
substrate (88.3% (w/w) protein) was obtained from a commercial supplier Carbery Food 118 
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Ingredients (Ballineen, Ireland). All other chemicals were obtained from Sigma Aldrich and 119 
were of analytical grade unless otherwise stated. 120 
 121 
2.2. Enzymatic hydrolysis of whey proteins and NF fractionation of the hydrolysate 122 
The WPH was generated using a food-grade pancreatic proteinase preparation at 123 
semi-pilot scale (200 L) as described by Nongonierma and FitzGerald (2013b). After 4 h 124 
hydrolysis, heat inactivation of the enzyme preparation was achieved by continuous heating 125 
to 85°C with 25 s holding time in a Unison H17 plate heat exchanger (Unison Engineering 126 
Services Ltd., Limerick, Ireland). The hydrolysate was then nanofiltered using a membrane 127 
housing containing 200 Da molecular weight cut off (MWCO) spiral wound Synder Filtration 128 
NF membranes, NFX-2A-3838 with 31 mil spacer, at 50°C and 22 bar inlet operating 129 
pressure. NF was conducted until 10.5% (w/v) solids were reached in the retentate. Different 130 
samples were collected throughout the process (hydrolysate, 200 Da permeate and 200 Da 131 
retentate). These were freeze-dried (FreeZone 18L, Labconco, Kansas City, U.S.A.) and 132 
stored at -20°C until utilisation. 133 
 134 
2.3. Determination of total nitrogen 135 
Total nitrogen content of the WPH, NF permeate and retentate was determined in 136 
triplicate (n=3) by Kjeldahl analysis as previously described by Connolly, Piggott, and 137 
FitzGerald (2013), with a KjelFlex K-360 (BUCHI Labortechnik AG, Flawil, Switzerland). A 138 
conversion factor of 6.38 was used to calculate the protein equivalent in the different samples 139 
(Cerbulis, Woychik, & Wondolowski, 1972). 140 
 141 
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2.4. DPP-IV inhibition assay 142 
The protein hydrolysates were dispersed in HPLC-grade water at concentrations 143 
ranging from 31.3 × 10
-3
 to 5.0 mg mL
-1
 (final concentration). The DPP-IV inhibition assay 144 
was carried out as described by Nongonierma and FitzGerald (2013a). Each sample was 145 
analysed in triplicate. The DPP-IV half maximal inhibitory concentration (IC50) values were 146 
determined by plotting the percentage inhibition as a function of the concentration of test 147 
compound. 148 
 149 
2.5. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) of the 150 
hydrolysates and associated NF fractions 151 
The peptide profiles of the different samples were determined by RP-UPLC (Acquity 152 
- Waters, Dublin, Ireland) equipped with a 2.1  50 mm, 1.7 µm Acquity UPLC BEH C18 153 
column and an Acquity BEH C18 1.7 μm vanguard pre-column (Waters) as described by 154 
Nongonierma and FitzGerald (2012). For each sample, 50 µg (final concentration: 5 g L
-1
, 155 
injection volume: 10 µL) was injected onto the column. 156 
 157 
2.6. Peptide detection with liquid chromatography-mass spectrometry (LC-MS/MS) 158 
Samples were analysed by LC-MS/MS using a UPLC system (Waters) coupled to a 159 
quadrupole time-of-flight mass spectrometer (Impact HD™, Bruker Daltonics GmbH, 160 
Bremen, Germany). The MS was equipped with an electrospray ionisation (ESI) source used 161 
in positive ion mode. Instrument control and data acquisition were performed using Hystar™ 162 
software (Bruker Daltonics). 163 
Two complementary chromatographic modes were used for peptide separation prior 164 
to MS/MS analysis. RP and HILIC separations were used as compounds elute differently on 165 
these two matrices. RP-UPLC was performed using an Acquity BEH C18 column (2.1 x 150 166 
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mm, 1.7 µm) equipped with an Acquity BEH C18 1.7 μm vanguard pre-column (Waters). 167 
Mobile phase A was 0.1% (v/v) TFA in water whereas mobile phase B was 0.1% (v/v) TFA 168 
in MeCN. A linear gradient from 100 to 60% solvent A was applied for 120 min at a flow 169 
rate of 0.2 mL min
-1
. The column temperature was maintained at 40ºC. Samples were diluted 170 
in solvent A (final concentration of 5 g L
-1
) and filtered through 0.2 µM cellulose acetate 171 
filters before injection (2 µL). The UPLC system was equipped with a tunable UV detector 172 
set at 214 and 280 nm. The operating conditions were initially investigated to obtain the 173 
optimal separation of a complex milk protein hydrolysate sample. MS measurements were 174 
performed over a 70-700 m/z acquisition range. MS data were processed on Compass 175 
DataAnalysis 4.0 SP5 (Bruker Daltonics). 176 
HILIC chromatography was performed on an Acquity BEH amide column as 177 
previously described by Le Maux et al. (2015). The MS operating conditions were similar to 178 
those described above for RP-LC-MS/MS. 179 
 180 
2.7. Retention time prediction models and identification of short peptides by LC-MS  181 
Retention time prediction models were coupled to MS/MS data in order to improve 182 
peptide identification. The HILIC retention time model used was as described by Le Maux et 183 
al. (2015). Another model based on RP separation was developed herein using a similar 184 
strategy. Briefly, a training set of 153 standard peptides was used to determine the algorithm 185 
of the RP prediction model. These peptides were selected based on their range of 186 
hydrophilicity/hydrophobicity, peptide size (di- to tetrapeptides) and sequence. Matlab 187 
(version 2014b, The MathWorks Inc., Natick, MA, USA) was used to generate coefficients 188 
representing the impact of each amino acid on peptide apparent hydrophobicity. These 189 
hydrophobicity coefficients were determined depending on amino acid location (C-, N-190 
terminus or within the peptide sequence). The apparent hydrophobicity of a peptide (H) was 191 
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determined as the sum of each amino acid coefficient in the peptide chain (Meek, 1980). 192 
Subsequently, a linear regression was performed to predict retention time using both peptide 193 
sequence and length. The RP retention time model was statistically validated as previously 194 
described (Le Maux et al., 2015). 195 
The approach to identify short peptides within the nanofiltrate was also as described 196 
by Le Maux et al. (2015). A list of potential peptides, which corresponded to the properties of 197 
the detected peptides, was generated using a mass tolerance set at 0.1 Da. An in-house bovine 198 
milk protein database was built in order to discard non relevant peptides using all the 199 
available genetic variants, given in PubMed, of the major bovine milk proteins (β-200 
lactoglobulin, α-lactalbumin, bovine serum albumin, lactoferrin, αs1-, αs2-, β- and κ-casein). 201 
As several peptide sequences could correspond to the retention time and molecular mass of 202 
one peptide signal, these potential peptides were ranked as a function of their retention time 203 
differences (observed minus predicted retention times). 204 
 205 
 206 
2.8. Statistical analysis 207 
Means comparison was carried out using a one way ANOVA. Post-hoc tests were 208 
conducted following a Student-Newman-Keuls test using SPSS (version 22, SPSS Inc., 209 
Chicago, IL, USA) at a significance level P < 0.05. 210 
 211 
 212 
3. Results 213 
 214 
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3.1. Peptide profile of the WPH and associated NF fractions 215 
The RP-UPLC profiles for the WPH and its associated NF retentate and permeate are 216 
depicted in Fig. 1. The WPH and its NF retentate had similar peptide profiles showing a large 217 
number of peptide peaks eluting during the first 25 min of the MeCN gradient. In contrast, 218 
the NF permeate shows a less complex profile, with 3 main peaks eluting at 2.9, 4.8 and 7.7 219 
min. Similar peaks were also present in the WPH and the NF retentate, but at a lower 220 
intensity in the WPH than in the NF permeate. 221 
 222 
3.2. DPP-IV inhibitory activity of the WPH and associated NF fractions 223 
The DPP-IV IC50 values were 0.94 ± 0.24, 0.82 ± 0.13 and 0.66 ± 0.08 mg protein 224 
equivalent mL
-1
 for the WPH, NF retentate and permeate, respectively (Table 1). The DPP-IV 225 
IC50 for the NF permeate was significantly lower (P < 0.05) than that of the WPH and NF 226 
retentate. 227 
The NF permeate peptide profile showed a significantly reduced complexity (i.e., 228 
three main peptide peaks, Fig. 1). In addition, it displayed the highest DPP-IV inhibitory 229 
potency (Table 1). Therefore, LC-MS/MS analysis was applied to the NF permeate with a 230 
view to specifically identify short peptides contributing to the overall DPP-IV inhibitory 231 
properties of the WPH. 232 
 233 
3.3. Development of the reverse phase (RP) retention time prediction (RTpred) model 234 
The retention time prediction (RTpred) model was best described by the equation: 235 
𝑅𝑇𝑝𝑟𝑒𝑑  =
(𝐻−𝑎)
𝑏
          (Equation 1) 236 
The constants a and b were optimised through iterations of the amino acid 237 
hydrophobic coefficients and were defined in the operating conditions as - 1.384 ± 0.194 and 238 
0.9383 ± 0.006, respectively. The established amino acid hydrophobic coefficients that 239 
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allowed equation 1 to have the highest R
2 
are described in Supplementary Table S1. The 240 
peptide apparent hydrophobicity (H) was calculated using these coefficients. Tryptophan (W) 241 
had the highest hydrophobic coefficient, followed by phenylalanine (F) > leucine (L) and 242 
isoleucine (I) > tyrosine (Y), methionine (M) and valine (V). The basic and polar with 243 
uncharged side group amino acids exerted a very low influence on the retention time. 244 
However, depending on their position in the peptide sequence, some of these amino acids 245 
displayed a large difference between their hydrophobic coefficients. For instance, the 246 
hydrophobic coefficients for threonine (T) were low but displayed large variations (from -247 
5.387 to 5.563 in C- and N-terminus, respectively) compared to W coefficients which were 248 
high but varied within a narrow range (from 25.659 to 28.989 in N- and C-terminus, 249 
respectively). The position of some amino acids in the peptide sequence had an impact on the 250 
retention time. Indeed, twenty-five pairs of homologous peptides (peptides with the same 251 
amino acid composition but in a different sequence) were analysed, nineteen of these peptides 252 
had significantly (P < 0.05) different retention time (data not shown). For example, the 253 
dipeptides WD and DW had retention times of 22.076 ± 0.077 and 33.477 ± 0.019 min, 254 
respectively. There were no peptides eluting before 2.1 min, which represented the void 255 
volume of the column. 256 
The RP retention time model was statistically validated, having an R
2
 of 0.978, a F-257 
statistic of 2.23 × 10
4
 with an extremely low P-value (P < 5 × 10
-324
) and a Durbin–Watson 258 
statistic value of 1.762. The Cook’s distance and the residual plots of this prediction model 259 
were considered acceptable as no outliers could be determined (data not shown). The root 260 
mean squared error of the model, as well as the root mean squared errors of two cross-261 
validations, leave-one-out and tenfold cross-validations, revealed the robustness of the model 262 
as the values were of 2.724, 2.992 and 2.995, respectively. The predicted retention time had 263 
intervals of 6.8 and 8.4 min for confidence levels of 95 and 99%, respectively (Fig. 2). 264 
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Therefore, a 10 min difference interval between the observed and predicted retention times 265 
was used as a cut off to select the possible peptide candidates. 266 
 267 
3.4. Identification of peptides within the NF permeate of the WPH 268 
A relatively low number (16) of compounds could be detected by LC-MS/MS within 269 
the NF permeate (Table 2). For the first time, the peptides of this NF permeate sample were 270 
subsequently identified. These compounds were analysed by correlating their molecular 271 
mass, retention time and MS/MS spectrum. As several sequences could match the properties 272 
of one compound, these sequences were defined as potential peptides within the NF 273 
permeate. The presence of potential peptide sequences was searched against an in-house 274 
bovine milk protein database in order to reject non-relevant peptides. Eight amino acids, 275 
seven dipeptides and one tetrapeptide were detected within the NF permeate. The potential 276 
peptide sequences were ranked based on their highest probability of occurrence (Table 2). 277 
This was achieved by using the two retention time models (RP and HILIC) to allow for a 278 
more accurate ranking of homologous peptides. For instance, the molecular mass of peptide 279 
No. 10 in Table 2 corresponded to 6 (GI, GL, IG, LG, AV and VA) potential peptide 280 
sequences, but only 5 (GI, GL, IG, LG and AV) of these had predicted retention times that 281 
were within 10 min of the observed peptide retention time. Moreover, these potential peptides 282 
were ranked based on their retention time differences (predicted versus observed retention 283 
times), with GI and GL having the highest probability, followed by IG and LG, and then AV. 284 
VA was excluded as a potential peptide candidate for compound No. 10 as the difference 285 
between its predicted and observed retention time in RP conditions was > 10 min. Y, F and 286 
W showed the highest intensities by UV detection at 214 nm in HILIC-MS/MS and RP-287 
MS/MS, which is in accordance with the peptide profile in Fig. 1 where these amino acids 288 
eluted at 2.9, 4.8 and 7.7 min, respectively. 289 
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 290 
3.5. Confirmatory study of DPP-IV inhibitory activity with synthetic peptides 291 
Several of the peptide sequences identified within the NF permeate have previously 292 
been identified in the literature (Table 2). Therefore, only the peptide sequences which had 293 
not previously been reported for their DPP-IV inhibitory properties were synthesised for 294 
further confirmatory study. It was conducted to determine which compounds within the NF 295 
permeate were bioactive. Previously published DPP-IV IC50 values for the amino acids found 296 
within the NF permeate are shown in Table 3 (Nongonierma, Mooney, Shields, & FitzGerald, 297 
2013). In addition, IW, LW, WL, WI VA, GL, FW, WF and VL have also been previously 298 
evaluated for their DPP-IV inhibitory potential (Lan, Ito, Ito, & Kawarasaki, 2014; Lan et al., 299 
2015; Nongonierma & FitzGerald, 2013a, 2013c; Tulipano et al., 2011). Five peptides 300 
reported for the first time (CIVL, LCVL, IG, IY and GI) were evaluated for their DPP-IV 301 
inhibitory properties in this study (Table 2). Their DPP-IV IC50 values are reported in Table 302 
3. WL was the most potent for DPP-IV inhibitory peptide identified within the NF permeate, 303 
with an IC50 value of 43.6 µM. The NF permeate contained four potential DPP-IV inhibitory 304 
peptides, VL, VA, WL and WI, with IC50 values < 170 µM. 305 
 306 
 307 
 308 
 309 
4. Discussion 310 
 311 
The fractionation of complex peptide mixtures followed by the identification of 312 
bioactive peptides is of major interest as it allows further optimisation of the protein 313 
hydrolysis processes, with the view of increasing the potency of bioactive ingredients. The 314 
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NF and LC-MS/MS approach described herein allowed for the development of an integrated 315 
strategy aimed at the identification of potent short DPP-IV inhibitory peptides within a WPH. 316 
Previous studies have identified short milk protein-derived peptides within milk protein 317 
hydrolysate fractions (Lacroix & Li-Chan, 2014; Silveira, Martínez-Maqueda, Recio, & 318 
Hernández-Ledesma, 2013). However, the peptides reported were  4 amino acid residues in 319 
length. To our knowledge, it is the first time that di- and tripeptides with DPP-IV inhibitory 320 
activity are identified using LC-MS/MS within a milk protein hydrolysate fraction. 321 
Identification of short peptide sequences in complex food protein hydrolysates is 322 
challenging. Therefore, a new RP retention time prediction model focused on short peptide 323 
(up to four amino acids in length) separation was developed. It was based on the amino acid 324 
location within a peptide and its impact on peptide apparent hydrophobicity. Previous studies 325 
have also highlighted the impact of N- and C-terminal amino acids on the retention time of 326 
peptides in RP conditions (Krokhin, 2006; Tripet et al., 2007). These studies showed a similar 327 
trend to the model herein concerning the influence of each residue on peptide hydrophobicity 328 
with W, F, L and I having the highest impact. Interestingly, the elution order of peptides 329 
under RP and HILIC conditions were not the mirror image of each other as the contribution 330 
of each amino acid to the RP retention time was not the exact opposite of their contribution in 331 
HILIC conditions (Le Maux et al., 2015). Therefore, the differences between the two 332 
separation modes showed that HILIC- and RP-LC were complementary peptide separation 333 
methods. The use of complementary separation methods has previously been shown to 334 
significantly enhance peptide identification (Harscoat-Schiavo et al., 2012). Peptide 335 
identification was improved herein by focusing on di- to tetrapeptides and discriminating on 336 
the basis of the amino acid position within the peptide chain. This peptide identification 337 
strategy permitted the compilation of a short ranked list of potential sequences for the 338 
unknown peptides detected in the NF permeate (Table 2). 339 
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Previous studies were performed on the WPH fractionation using 2 kDa ultrafitration 340 
membrane and an hydrophobic solid-phase extraction (SPE) resin (Nongonierma & 341 
FitzGerald, 2013b). When the SPE fraction was analysed by LC-MS/MS in the previous 342 
study, 45 potential peptides were identified. However, this number of potential peptide 343 
candidates was too high to distinguish which peptide sequence(s) may be responsible for the 344 
DPP-IV inhibitory properties (Le Maux et al., 2015). The NF fractionation approach 345 
described herein allowed the generation of a fraction with a reduced complexity (16 346 
compounds) and a significant higher DPP-IV inhibitory activity than the WPH. While the 347 
IC50’s of the different samples were of the same order, this approach proved that short 348 
peptides were responsible in part for the bioactivity of the WPH. This NF permeate fraction 349 
was characterised in the present study for the first time. The masses of the compounds 350 
detected in the NF permeate were compatible with the nominal MWCO (200 Da) of the 351 
membrane as it contained free amino acids and short peptides (2-4 amino acid in length). As 352 
this study focused on short peptides, the NF permeate was the only sample which was further 353 
characterised by LC-MS/MS. Moreover, the NF permeate was the most potent fraction and 354 
displayed a reduced peptide profile complexity.  355 
The DPP-IV inhibitory properties of three amino acids found within the NF permeate 356 
(L, M and W) had previously been demonstrated. However, their DPP-IV inhibitory potency 357 
was quite low (IC50 > 2300 µM (Nongonierma et al., 2013)). The most potent peptides (IC50 358 
< 170 µM) found within the NF permeate of WPH were WI, WL, VA and VL. This result 359 
was in agreement with a previous in silico study using a peptide alignment strategy, which 360 
showed that peptides possessing a W at the N-terminus and/or a P at position 2 generally had 361 
DPP-IV IC50’s < 200 µM (Nongonierma & FitzGerald, 2014). Interestingly, WL (IC50 = 43.6 362 
µM), the most potent peptide within the NF permeate sample was of the same order of DPP-363 
IV inhibitory potency as LKPTPEGDL (IC50 = 45 µM) and IPAVF (IC50 = 44.7 µM), which 364 
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had previously been identified within whey protein hydrolysates (Lacroix & Li-Chan, 2014; 365 
Silveira et al., 2013). It was shown in previous studies that specific milk protein-derived 366 
peptides with a DPP-IV IC50 value of the same order as the most potent peptides identified 367 
within the NF permeate displayed an antidiabetic activity in vivo. This was the case with the 368 
DPP-IV inhibitory peptides VAGTWY (β-lactoglobulin f15-20; IC50 = 174 µM) and 369 
LPQDIPPL (β-casein f70–77; IC50 = 46 µM) which mediated insulinotropic and serum 370 
glucose lowering activities in small animals (Uchida, Ohshiba, & Mogami, 2011; Uenishi, 371 
Kabuki, Seto, Serizawa, & Nakajima, 2012). The results presented herein need to be assessed 372 
in vivo in order to understand how they may affect serum glucose regulation. 373 
The interest in focusing on short (di- tri and tetra-) peptides was related to the fact that 374 
these sequences may be bioavailable as they may be able to survive gastrointestinal digestion 375 
and also display an increased intestinal permeability compared to larger peptides or free 376 
amino acids. Permeation of short peptides (di- and tripeptides) through Caco-2 cell 377 
monolayers has been reported in in vitro studies (Shimizu, Tsunogai, & Arai, 1997). Human 378 
studies have also shown that short peptides have the ability to cross the gut barrier as they 379 
were identified in the serum following the ingestion of a yoghurt enriched in the 380 
lactotripeptides LPP and VPP (Foltz et al., 2007) or milk protein hydrolysates (Morifuji et al., 381 
2010). In silico digestion of the most potent peptides (VL, VA, WL and WI) indicated that 382 
VA and VL may be stable to gastrointestinal enzymes (data not shown). However, 383 
confirmatory in vitro and in vivo studies are needed. 384 
 385 
 386 
5. Conclusion 387 
 388 
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A new strategy to identify short peptides was developed, being innovative in the 389 
utilisation of a RP and HILIC approach designed for di- to tetrapeptides. This new approach 390 
allowed the differentiation between homologous peptides. This method was optimised to 391 
identify short peptides which cannot usually be identified by MS/MS and de novo searches. 392 
The use of further separation methods prior to MS, such as ion-exchange or capillary 393 
electrophoresis, may lead to the determination of a unique peptide sequence for each 394 
compound detected. 395 
To our knowledge, NF has not been previously employed for the fractionation and 396 
further identification of DPP-IV inhibitory peptides. Specific short peptide sequences found 397 
within the NF permeate of the WPH were shown to be relatively potent DPP-IV inhibitory 398 
peptides (IC50 < 170 µM). This demonstrated that short peptides were also responsible for the 399 
overall DPP-IV inhibitory potential of the WPH. Furthermore, these peptides were predicted 400 
in silico to be relatively stable to gastrointestinal digestion. However, these results would 401 
need to be confirmed following in vitro and in vivo digestion of the fraction.  402 
The results reported in this study demonstrated that, with the strategy employed, it 403 
was possible to improve the fractionation and subsequently the detection of short DPP-IV 404 
inhibitory peptides in a milk protein hydrolysate. The strategy described herein is highly 405 
relevant to the discovery of short bioactive peptide sequences.  406 
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Table captions 
 
Table 1 Dipeptidyl peptidase IV (DPP-IV) inhibitory potency (concentration of 
sample inducing 50% DPP-IV inhibition - IC50) of the whey protein hydrolysate (WPH) and 
its associated nanofiltration (NF) retentate and permeate. 
 
Table 2 Peptide and free amino acid identification in the nanofiltration (NF) whey 
protein hydrolysate (WPH) permeate using the in-house milk protein database and the reverse 
phase (RP) and hydrophilic interaction liquid chromatography (HILIC) retention time 
prediction models. The number of possible compounds was based on the Mw determined 
experimentally by LC-MS/MS with an error of 0.1 Da. 
 
Table 3 Concentration of peptides, identified within the nanofiltration (NF) whey 
protein hydrolysate (WPH) permeate, inducing 50% inhibition (IC50) of dipeptidyl peptidase 
IV (DPP-IV). 
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Table 1 
 
Test sample DPP IV IC50 
(mg protein equivalent mL
-1
)
*
 
WPH 0.94 ± 0.24
b
 
WPH NF retentate 0.82 ± 0.13
b
 
WPH NF permeate 0.66 ± 0.08
a
 
 
*Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values 
with different superscript letters are significantly different (P < 0.05). The DPP-IV 
IC50 of IPI (diprotin A) was of 0.0013 ± 0.0002 mg mL
-1
. 
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Table 2 
 
Peptide 
No. 
Mw+H 
(Da) 
No. of peptides 
with the 
targeted Mw 
No. of potential sequences 
after the models and milk 
database 
Potential sequences 
(ranked in peptide 
order)* 
Sequences previously 
assessed for their DPP-IV 
inhibition** 
1 118.086 1 1 V V 
2 132.101 2 2 I, L I, L 
3 132.101 2 2 I, L I, L 
4 150.058 1 1 M M 
5 166.086 1 1 F F 
6 175.118 3 1 R R 
7 182.080 1 1 Y Y 
8 189.122 6 4 AV, VA > IG, GI AV, VA 
9 189.122 6 4 AV, VA > IG, GI AV, VA 
10 189.122 6 5 GI, GL > IG, LG > AV GL, LG, AV 
11 205.096 7 1 W W 
12 231.168 6 4 IV, VI, LV, VL IV, VI, LV, VL,  
13 295.165 6 4 IY, YI, LY, YL YI, LY, YL 
14 318.182 105 4 IW, WI, LW, WL IW, WI, LW, WL 
15 447.295 1082 2 CIVL > LCVL - 
 
* Sequences separated by a comma have the same probability of occurrence, whereas “>” showed the sequences with higher 
probability of occurrence. Novel peptides selected for the DPP-IV inhibitory confirmatory study are highlighted in bold. 
** Peptides previously identified for their DPP-IV inhibitory properties as described elsewhere (Lan et al., 2015; 
Nongonierma & FitzGerald, 2014). 
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 1 
 2 
Table 3 3 
Peptide sequence /amino acid DPP IV IC50 (M)* Reference 
V nm (Nongonierma et al., 2013) 
L 3419.25 (Nongonierma et al., 2013) 
I nm (Nongonierma et al., 2013) 
M 2381.51 (Nongonierma et al., 2013) 
F nm (Nongonierma et al., 2013) 
W 4280.40 (Nongonierma et al., 2013) 
R nm (Nongonierma et al., 2013) 
Y nm (Nongonierma et al., 2013) 
IPI 3.73 ± 0.67
a
 this study 
CIVL nm this study 
LCVL nm this study 
IW nm (Nongonierma et al., 2013) 
LW 993.4 (Nongonierma & FitzGerald, 2013c) 
WL 43.6 (Nongonierma & FitzGerald, 2013c) 
WI 138.7 (Nongonierma & FitzGerald, 2013c) 
VA 168.2 (Nongonierma & FitzGerald, 2013a) 
AV nm (Lan et al., 2015) 
IG nm this study 
GI nm this study, (Lan et al., 2015) 
GL 2615 (Nongonierma & FitzGerald, 2013a) 
LG nm this study, (Lan et al., 2015) 
 29 
YI 1488.50 ± 229.79
c
 this study 
 nm (Lan et al., 2015) 
YL 940.20 ± 279.00
b
 this study 
 nm (Lan et al., 2015) 
IV nm (Lan et al., 2015) 
VI nm (Lan et al., 2015) 
LV nm (Lan et al., 2015; Tulipano, Sibilia, Caroli, & Cocchi, 
2011) 
VL 74 (Lan et al., 2014) 
IY nm this study 
LY nm (Lan et al., 2015) 
 
*Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values with a different superscript letters are 
significantly different (P < 0.05). nm: not measureable, i.e.,% DPP-IV inhibition < 50% when tested at the highest 
concentration evaluated during the dose response experiment. 
 4 
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Figure captions 
Fig. 1. Reverse-phase ultra-performance liquid chromatographic (RP-UPLC) profile at 214 
nm of (A) the whey protein hydrolysate (WPH), (B) its associated 200 Da retentate and (C) 
permeate. MeCN: acetonitrile. The amino acids Y, F and W elute at 2.9, 4.8 and 7.7 min, 
respectively. 
 
Fig. 2. Plot of predicted (RTpred) versus observed (RTobs) retention times of the set of 153 
training peptides. The RTobs corresponds to the mean of three replicates (n = 3). Peptide 
trendline, black solid line; confidence limits of the prediction at 95%, black dashed line; 
confidence limits of the prediction at 99%, grey solid line. 
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Supplementary Table S1. Hydrophobic coefficients of amino acid residues determined 
when the amino is present at the N-, C-terminus and within a peptide sequence. 
 
Amino acid N-t C-t Centre 
A 0 -0.82 5.06 
R 2.164 0.004 4.924 
N 0.472 -8.178 -0.308 
D 2.583 -7.877 2.933 
C 5.522 0.942 9.902 
E 2.426 -0.864 2.906 
Q 1.539 -2.441 0.829 
G -0.28 -0.8 0.09 
H 0.379 -0.141 4.839 
I 15.775 18.735 18.315 
L 15.999 20.719 20.889 
K 0.093 -3.007 2.213 
M 10.011 11.431 11.441 
F 22.133 27.033 23.143 
P 3.425 6.565 6.155 
S -2.818 -2.818 0.592 
T 5.563 -5.387 0.833 
W 25.659 28.989 28.539 
Y 11.12 11.22 14.41 
V 8.007 10.407 11.297 
 
N-t: coefficient for the amino acid in N-terminal position; C-t: 
coefficient for the amino acid in C-terminal position; Centre: 
coefficient for the amino acid inside the peptide sequence. 
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Supplementary Table S2. Results of the in silico digestion of the peptides identified within the nanofiltration (NF) permeate of the whey 1 
protein hydrolysate (WPH) with a dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) > 200 µM. The in silico 2 
digestion of the peptides was conducted with the peptide cutter of Matlab using pepsin, pancreatic elastase, trypsin and chymotrypsin. 3 
 4 
Parent peptide Enzyme Predicted amino acids / peptides 
released* 
CIVL PEPS CIVL 
 PEPS2 CIVL 
 TRYPS CIVL 
 ELAS CIV, L 
 CH-HI CIVL 
 CH-LO CIVL 
LCVL PEPS LCVL 
 PEPS2 LCVL 
 TRYPS LCVL 
 ELAS LCV, L 
 CH-HI LCVL 
 CH-LO L, CVL 
IW PEPS IW 
 PEPS2 IW 
 TRYPS IW 
 ELAS IW 
 CH-HI IW 
 CH-LO IW 
LW PEPS LW 
 PEPS2 LW 
 TRYPS LW 
 ELAS LW 
 CH-HI LW 
 CH-LO L, W 
AV PEPS AV 
 35 
 PEPS2 AV 
 TRYPS AV 
 ELAS AV 
 CH-HI AV 
 CH-LO AV 
IG PEPS IG 
 PEPS2 IG 
 TRYPS IG 
 ELAS IG 
 CH-HI IG 
 CH-LO IG 
GI PEPS GI 
 PEPS2 GI 
 TRYPS GI 
 ELAS GI 
 CH-HI GI 
 CH-LO GI 
GL PEPS GL 
 PEPS2 GL 
 TRYPS GL 
 ELAS GL 
 CH-HI GL 
 CH-LO GL 
LG PEPS LG 
 PEPS2 LG 
 TRYPS LG 
 ELAS LG 
 CH-HI LG 
 CH-LO L, G 
YI PEPS YI 
 PEPS2 YI 
 TRYPS YI 
 36 
 ELAS YI 
 CH-HI Y, I 
 CH-LO Y, I 
YL PEPS YL 
 PEPS2 YL 
 TRYPS YL 
 ELAS YL 
 CH-HI Y, L 
 CH-LO Y, L 
IV PEPS  IV 
 PEPS2  IV 
 TRYPS IV 
 ELASTASE IV 
 CH-HI IV 
 CH-LO IV 
VI PEPS VI 
 PEPS2 VI 
 TRYPS VI 
 ELASTASE VI 
 CH-HI VI 
 CH-LO VI 
LV PEPS LV 
 PEPS2 LV 
 TRYPS LV 
 ELASTASE LV 
 CH-HI LV 
 CH-LO L, V 
IY PEPS IY 
 PEPS2 IY 
 TRYPS IY 
 ELASTASE IY 
 CH-HI IY 
 37 
 CH-LO IY 
LY PEPS LY 
 PEPS2 LY 
 TRYPS LY 
 ELASTASE LY 
 CH-HI LY 
 CH-LO L, Y 
 
*Free amino acids and peptides predicted to be released by in silico digestion 
of the peptides within the nanofiltration (NF) permeate of the whey protein 
hydrolysate (WPH) using pepsin pH 1.3 (PEPS) and pH > 2.0 (PEPS2), 
pancreatic elastase (ELAS), trypsin (TRYPS), chymotrypsin high (CH-HI) 
and low (CH-LO) specificity. 
 
5 
 6 
 7 
 8 
 9 
